Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Prospective, Single-arm Study of Olverembatinib Plus Venetoclax and Dexamethasone in Patients of Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia

NCT06082934 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06082934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06082934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Prospective, Single-arm Study of Olverembatinib Plus Venetoclax and Dexamethasone in Patients of Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
Lead sponsor
Xijing Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 1, 2023
Completion date
November 1, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly-diagnosed ph+ acute lymphoblastic leukemia